Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeutics is expanding into a second autoimmune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback